Journal: Gut Microbes
Article Title: Blautia coccoides -derived metabolite trimethylamine-N-oxide exacerbates Alzheimer's disease progression via targeting HIF1α signaling
doi: 10.1080/19490976.2025.2605768
Figure Lengend Snippet: The TMAO level was correlated with dementia severity in AD patients, and TMAO treatment promoted Tau phosphorylation and oxidative stress in vitro . (A) Forest plot of MR analyses for the associations between TMAO and Dementia in AD, points represent beta estimates and 95% CI. (B) P301L-N2a cells were treated with 0, 1, 10, 20 and 50 μM TMAO, and cell viability was assessed using the CCK-8 method ( n = 5). (C) Representative Western blot images of p-Tau181 and p-Tau396 of Con group and TMAO group in P301L-N2a cells. (D) Quantitative analysis of p-Tau181 and p-Tau396 levels ( n = 3). The Con group was used as a reference value. (E) P301L-293T cells were treated with 0, 1, 10, 20 and 50 μM TMAO, and cell viability was assessed using the CCK-8 method ( n = 5). (F) Representative Western blot images of p-Tau181 and p-Tau396 of Con group and TMAO group in P301L-293T cells. (G) Quantitative analysis of p-Tau181 and p-Tau396 levels ( n = 3). The Con group was used as a reference value. (H) Representative immunofluorescence images of p-Tau396 of Con group and TMAO group in P301L-N2a cells. (I) Representative immunofluorescence images of p-Tau396 of Con group and TMAO group in P301L-293T cells. (J) Flow cytometry of ROS levels in Con and TMAO treated group of P301L-N2a. (K) Quantitative analysis of ROS in the two groups of P301L-N2a ( n = 3). (L) Flow cytometry of the ROS levels in the Con and TMAO treated group of P301L-293T. (M) Quantitative analysis of ROS in the two groups of P301L-293T ( n = 3). The image above: magnification 200×. Scale bar = 100 μm. The error bars indicate the SEM, * p < 0.05, ** p < 0.01, *** p < 0.01, and **** p < 0.0001.
Article Snippet: The cells were pretreated with TMAO (MCE, USA) for 16 h. After pretreatment, the cells were exposed to 1% O2 hypoxic conditions for an additional 6 h to stabilize HIF1α expression.
Techniques: Phospho-proteomics, In Vitro, CCK-8 Assay, Western Blot, Immunofluorescence, Flow Cytometry